What are the prerequisites and necessary evaluations before initiating apixaban (Eliquis) in a patient?

Prerequisites Before Starting Apixaban

Before initiating apixaban, you must assess renal function (serum creatinine), evaluate for prosthetic heart valves or triple-positive antiphospholipid syndrome (both absolute contraindications), determine appropriate dosing criteria (age, weight, creatinine), and ensure the patient is not at high risk for uncontrolled bleeding. 1

Absolute Contraindications to Assess

• Prosthetic heart valves: Apixaban use is not recommended in patients with prosthetic heart valves 1
• Triple-positive antiphospholipid syndrome: Apixaban is contraindicated due to increased thrombosis risk 1
• Severe renal impairment: For atrial fibrillation indication, avoid in patients with creatinine clearance <15 mL/min; for VTE treatment, patients with CrCl <25 mL/min were excluded from trials 2
• Severe hepatic impairment: Patients with transaminases >2 times upper limit of normal or total bilirubin >1.5 times upper limit of normal were excluded from clinical trials 2

Essential Laboratory and Clinical Assessments

Renal Function Evaluation

• Measure serum creatinine to calculate creatinine clearance, as approximately 27% of apixaban clearance occurs via renal excretion 3
• Renal function directly impacts dosing decisions for atrial fibrillation: patients with serum creatinine ≥1.5 mg/dL (combined with age ≥80 years or weight ≤60 kg) require dose reduction to 2.5 mg twice daily 1
• Severe renal impairment significantly prolongs drug half-life, affecting both efficacy and bleeding risk 4

Patient Characteristics for Dose Determination

For atrial fibrillation, reduced-dose apixaban (2.5 mg twice daily) is required if the patient has at least 2 of the following 3 criteria 1:

• Age ≥80 years
• Body weight ≤60 kg
• Serum creatinine ≥1.5 mg/dL

Standard dose (5 mg twice daily) is used for patients with fewer than 2 of these criteria 1

Hepatic Function Assessment

• Check liver function tests (transaminases and bilirubin) to identify hepatic impairment 2
• Apixaban is primarily metabolized via the liver (cytochrome P450 3A4-dependent), making hepatic function critical for drug clearance 2

Bleeding Risk Assessment

• Evaluate for active pathological bleeding, which is a contraindication to initiation 1
• Assess for conditions that increase bleeding risk: recent surgery, trauma, gastrointestinal ulcers, intracranial hemorrhage history 1
• Review concomitant medications that affect hemostasis, including NSAIDs, antiplatelet agents, and other anticoagulants 1

Drug Interaction Screening

• Identify strong dual inhibitors of CYP3A4 and P-glycoprotein (e.g., ketoconazole, ritonavir), which significantly increase apixaban exposure and may require dose adjustment or alternative therapy 3
• Screen for strong dual inducers (e.g., rifampin, carbamazepine), which decrease apixaban levels and reduce efficacy 3

Special Considerations for Specific Indications

For Venous Thromboembolism Treatment

• Confirm diagnosis of DVT or PE using validated diagnostic criteria (CTPA, ultrasound) before initiating treatment 2
• Assess clinical probability and ensure appropriate diagnostic workup is complete 2
• For PE specifically, stratify risk based on hemodynamic stability to determine if apixaban is appropriate (not for high-risk PE requiring thrombolysis) 2

For Post-Surgical Thromboprophylaxis

• Verify adequate hemostasis has been established post-operatively before starting apixaban 1
• Plan timing of first dose: 12-24 hours after hip or knee replacement surgery 1
• Assess for epidural catheter use: special timing considerations apply to avoid spinal/epidural hematoma 1

Neuraxial Anesthesia Risk Assessment

If the patient has or will have an indwelling epidural catheter or undergo spinal puncture, carefully evaluate the risk-benefit ratio 1:

• History of traumatic or repeated epidural/spinal punctures increases risk 1
• History of spinal deformity or spinal surgery increases risk 1
• Concomitant use of other drugs affecting hemostasis (NSAIDs, antiplatelets) increases risk 1

Patient Education Prerequisites

• Ensure the patient understands the importance of adherence, as premature discontinuation increases thrombotic event risk 1
• Educate about bleeding signs and symptoms requiring immediate medical attention 1
• Discuss the twice-daily dosing requirement and what to do if a dose is missed 1

Common Pitfalls to Avoid

• Do not use apixaban in patients with antiphospholipid antibody syndrome, particularly triple-positive patients; use VKA instead 2, 1
• Do not initiate during pregnancy or lactation, as NOACs are contraindicated in these populations 2
• Do not overlook the need for dose reduction when 2 of 3 criteria are met (age ≥80, weight ≤60 kg, creatinine ≥1.5 mg/dL) for atrial fibrillation indication 1
• Do not start apixaban without confirming adequate hemostasis in post-surgical patients 1